Pharmaceuticals News and Research

RSS

Savient second-quarter net loss decreases to $5.0 million

Savient Pharmaceuticals, Inc. reported financial results for the three and six months ended June 30, 2010. The net loss for the second quarter of 2010 was $5.0 million, or $0.07 per basic and diluted share, on total revenues of $1.0 million, compared with a net loss of $54.8 million, or $0.92 per basic and diluted share on total revenues of $0.7 million for the second quarter of 2009.

4 Aug 2010

Carfilzomib could become new option for patients with relapsed myeloma, IMF says

The International Myeloma Foundation, the oldest and largest foundation dedicated to improving the life and care of myeloma patients, today said promising data suggest a new drug called carfilzomib could become an important new option for patients whose myeloma stops responding to other therapies.

4 Aug 2010

Victory Pharma acquires assets of MiddleBrook Pharmaceuticals

Victory Pharma, Inc. today announced that it has completed the acquisition of substantially all of the assets of MiddleBrook Pharmaceuticals, Inc..

4 Aug 2010

Access Pharmaceuticals initiates Phase I/II dose escalating study for Thiarabine

Access Pharmaceuticals, Inc., today announced it has initiated a Phase I/II dose-escalating study of its proprietary, anti-cancer drug, Thiarabine, a nucleoside analog for patients with hematologic malignancies (cancers of the blood). The primary objective of the study is to determine the maximum tolerated dose (MTD) in two different dosing schedules with various leukemias and lymphomas and recommended Phase II dose. The program is being led by Hagop Kantarjian, M.D., Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.

4 Aug 2010

European Commission grants Teva approval for acquisition of ratiopharm

Teva Pharmaceutical Industries Ltd. announced today that the Company received approval from the European Commission to proceed with its acquisition of ratiopharm.

4 Aug 2010

Simulations Plus releases MedChem Studio software for drug discovery

Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, has announced the launch of its MedChem Studio™ software for drug discovery.

4 Aug 2010

Trius prices 10,000,000 shares initial public offering

Trius Therapeutics, Inc., a biopharmaceutical company developing innovative antibiotics for serious, life-threatening infections, announced today the initial public offering of 10,000,000 shares of its common stock at a price of $5.00 per share. The common stock is expected to begin trading on the NASDAQ Global Market on August 3, 2010 under the trading symbol "TSRX." Trius has granted the underwriters a 45 day option to purchase up to 750,000 shares of its common stock at the initial public offering price to cover over-allotments, if any.

4 Aug 2010

Arena reports lower net loss of $28.80M for second-quarter 2010

Arena Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010, and recent developments, including the successful Pre-Approval Inspection, or PAI, of the company's Swiss drug product manufacturing facility by the US Food and Drug Administration, or FDA.

4 Aug 2010

Cornerstone licenses global rights to alpha-7 technology to Targacept

Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that the Company has licensed to Targacept, Inc. the worldwide rights to its nicotinic-receptor based patents and library of preclinical compounds that target the alpha-7 or other nicotinic receptors originally licensed to Cornerstone from the Feinstein Institute for Medical Research.

4 Aug 2010

Agilent Technologies signs MoU with Government of Malaysia to intensify IPHARM's research activities

Agilent Technologies Inc. today signed a Memorandum of Understanding (MoU) with the Government of Malaysia through the Malaysian Institute of Pharmaceuticals and Nutraceuticals (IPHARM), an agency under the Ministry of Science, Technology and Innovation (MOSTI), to promote and develop cooperation in biotechnology.

4 Aug 2010

Enzon second-quarter loss from continuing operations reduces to $5.4 million

Enzon Pharmaceuticals, Inc. today announced its financial results for the second quarter of 2010. For the second quarter of 2010, Enzon reported a loss from continuing operations of $5.4 million or $0.09 per diluted share, as compared to a loss of $19.7 million or $0.43 per diluted share for the second quarter of 2009.

4 Aug 2010

Akorn second-quarter consolidated revenue increases 24% to $20.2 million

Akorn, Inc., a niche generic pharmaceutical company, today reported financial results for the second quarter ended June 30, 2010.

4 Aug 2010

Excaliard reports positive results from EXC 001 Phase 2 clinical trial for reducing scar severity

Excaliard Pharmaceuticals, Inc., today announced positive results from its Phase 2 clinical trial of EXC 001, a new chemical entity for reducing fibrosis. Results showed that EXC 001 treatment significantly reduced scar severity in subjects undergoing an elective abdominoplasty compared to placebo.

4 Aug 2010

Warnings on stop smoking drug Champix

The smoking cessation drug Champix (sold in the US as Chantix) has allegedly made fifteen people commit suicide since January 2008 in Australia. Another 191 patients have reported suicidal thoughts and related effects. The latest available figures from the Therapeutic Goods Administration (TGA) suggest a doubling in the numbers of suicides linked to Champix (Varenicline) since July last year with six people committing suicide.

3 Aug 2010

Impax Laboratories total revenue for second-quarter 2010 increases to $153.1 million

Impax Laboratories, Inc. today reported strong growth in the second quarter of 2010 due to an increase in sales from its Global Product sales channel. Total revenue increased $94.7 million to $153.1 million driven by continued strong sales of generic Adderall XR and generic Flomax for which there were no amounts in the second quarter of 2009, as well as increased sales of the Company's fenofibrate products.

3 Aug 2010

MAP Pharmaceuticals reports net loss of $12.5M for second-quarter 2010

MAP Pharmaceuticals, Inc. today announced financial results for the second quarter ended June 30, 2010.

3 Aug 2010

POZEN reports $16.2M net income for second-quarter 2010

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the second quarter ended June 30, 2010.

3 Aug 2010

ImpactRx launches smart-phone application for physicians

ImpactRx, Inc., the pioneering force in measuring the impact of pharmaceutical promotion on the behavior of the nation's highest prescribing physicians, today announced the launch of an application for physicians that provides pharmaceutical companies with timely and actionable insight into drug therapy promotion and treatment activity. ImpactRx is leveraging the capabilities of this newly available smart-phone application by using iPhone with its longitudinal physician network.

3 Aug 2010

Rigel reports net income of $27.0M for second-quarter 2010

Rigel Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2010.

3 Aug 2010

Titan completes 60% enrollment in confirmatory Phase 3 clinical study of Probuphine for opioid addiction

Titan Pharmaceuticals, Inc. today announced that patient enrollment is more than 60% complete in the confirmatory Phase 3 clinical study of Probuphine for the treatment of opioid addiction, and the study is expected to complete enrollment by early fourth quarter of this year, which is almost three months ahead of schedule.

3 Aug 2010